Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-02

Lead Sponsor: Yale University

Registration Number: NCT00002948

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00040872

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Phase 2

Terminated

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2023-01-09

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 5

Registration Number: NCT00014443

Locations: 🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-05

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 24

Registration Number: NCT00003194

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: topotecan hydrochloride
Drug: etoposide

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-09

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT00041015

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT00003065

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: doxorubicin hydrochloride
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00006125

Locations: 🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸
Lenoir Memorial Hospital Cancer Center, Kinston, North Carolina, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 73 locations

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Primary Peritoneal Carcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine Hydrochloride
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Topotecan Hydrochloride
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-16

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 4312

Registration Number: NCT00011986

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005990

Locations: 🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States

Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00025311

Locations: 🇫🇷
CHU Pitie-Salpetriere, Paris, France
🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy